Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?

Postow, Michael A

Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse? [electronic resource] - Clinical advances in hematology & oncology : H&O May 2018 - 353-355 p. digital

Publication Type: Journal Article

1543-0790


Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Chemotherapy, Adjuvant--methods
Combined Modality Therapy--methods
Gene Expression Regulation, Neoplastic
Humans
Imidazoles--therapeutic use
Immunotherapy--methods
Interferon alpha-2
Interferon-alpha--therapeutic use
Ipilimumab--therapeutic use
MAP Kinase Kinase 1--antagonists & inhibitors
Melanoma--drug therapy
Nivolumab
Oximes--therapeutic use
Prognosis
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Proto-Oncogene Proteins B-raf--antagonists & inhibitors
Pyridones--therapeutic use
Pyrimidinones--therapeutic use
Randomized Controlled Trials as Topic
Recombinant Proteins--therapeutic use
Recurrence
Skin Neoplasms--drug therapy
Survival Analysis